SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.


Already have an account? Log in here

Analysis of Breyanzi in CLL/SLL Demonstrates Long Survival in Patients Achieving CR; Yescarta Reduces Risk of Death in 2L LBCL; Tecartus’s RW Study Shows Improved Results when Compared with ZUMA-2; ASCO 2023 Analysis 5

Here is a brief preview of this blast: ASCO 2023 Analysis 5: BMS and Gilead (Kite) presented clinical outcomes from their autologous CD19 CAR-Ts in hematological malignancies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered: